Fig. 6
From: Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition

Validation of key senescence markers in total proteome and phosphoproteome. (a) Mean Log2 ratio of LMNB1 protein abundance of Palbociclib-treated cells versus their respective controls. (b) Mean Log2 ratio of KI67 protein abundance of Palbociclib-treated cells versus their respective controls. (c) Mean Log2 ratio of GLB1 protein abundance of Palbociclib-treated cells versus their respective controls.